BioSight
Companies
Maze Therapeutics, Inc. logo

MAZE

NASDAQSOUTH SAN FRANCISCO, CA
Maze Therapeutics, Inc.

Maze Therapeutics is a clinical-stage biotech company developing small molecule therapeutics for rare genetic diseases and other indications using its Compass platform, which leverages human genetics data to identify and validate therapeutic targets. The company's lead programs include MZE829 and MZE782, though specific indications and development timelines are not detailed in this excerpt.

Price history not yet available for MAZE.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar